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Abstract 
Objective: Regulation of intercellular adhesion molecule (ICAM)-1 in retinal endothelial cells is a promising drug-
gable target for retinal vascular diseases. The ICAM-1-related (ICR) long non-coding RNA stabilizes ICAM-1 transcript, 
increasing protein expression. However, studies of ICR involvement in disease have been limited as the promoter is 
uncharacterized. To address this issue, we undertook a comprehensive in silico analysis of the human ICR gene pro-
moter region.
Results: We used genomic evolutionary rate profiling to identify a 115 base pair (bp) sequence within 500 bp 
upstream of the transcription start site of the annotated human ICR gene that was conserved across 25 eutherian 
genomes. A second constrained sequence upstream of the orthologous mouse gene (68 bp; conserved across 27 
Eutherian genomes including human) was also discovered. Searching these elements identified 33 matrices pre-
dictive of binding sites for transcription factors known to be responsive to a broad range of pathological stimuli, 
including hypoxia, and metabolic and inflammatory proteins. Five phenotype-associated single nucleotide polymor-
phisms (SNPs) in the immediate vicinity of these elements included four SNPs (i.e. rs2569693, rs281439, rs281440 and 
rs11575074) predicted to impact binding motifs of transcription factors, and thus the expression of ICR and ICAM-1 
genes, with potential to influence disease susceptibility. We verified that human retinal endothelial cells expressed 
ICR, and observed induction of expression by tumor necrosis factor-α.
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Introduction
Background
Retinal vascular diseases occur commonly and represent 
a major cause of blindness in developing and developed 
nations. These conditions include diabetic retinopathy, 
major retinal vessel occlusions, sickle cell retinopathy, 
retinopathy of prematurity and uveitis [1]. A key fea-
ture of the pathology of any retinal vasculopathy is over-
expression of endothelial adhesion molecules in response 
to stimuli such as inflammatory molecules, toxic metabo-
lites and hypoxia. The increased expression of adhesion 
molecules promotes leukocyte interactions with the 
endothelium, resulting in leukostasis, migration of leu-
kocytes into the tissue and/or endothelial cell apoptosis 
[1]. Present evidence [2–6] implicates intercellular adhe-
sion molecule (ICAM)-1, which is expressed at relatively 
high levels on human retinal endothelium [7], as a critical 
player.
Targeting retinal endothelial ICAM-1 for therapeutic 
purposes has been entertained [1]. However, ICAM-1 
plays an important role in host immune defense and 
complete blockade would pose the risk of infection. In 
previously published work [8], we showed that a stimu-
lus-induced increase in ICAM-1, but not its basal level, 
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might be reduced by manipulating gene expression. Small 
interfering RNA knock-down of the multi-functional 
transcription factor (TF), nuclear factor κ-light-chain-
enhancer of activated B cells (NF-κB)1, in human retinal 
endothelial cells significantly reduced a tumor necrosis 
factor (TNF)-α-induced increase in ICAM-1 expression, 
but did not alter constitutive ICAM-1 expression. Impor-
tantly, NF-κB1 knock-down also significantly reduced 
leukocyte binding to TNF-α-stimulated human retinal 
endothelial cell monolayers, but did not impact baseline 
binding.
Rationale
Specificity is an important consideration for success in 
planning a treatment approach that involves manipulat-
ing ICAM-1 expression. One candidate molecule with 
a primary function in regulating ICAM-1 expression 
is ICAM-1-related (ICR), which is a long non-coding 
(lnc)RNA transcribed from the anti-sense DNA strand 
overlapping the ICAM1-ICAM4-ICAM5 gene cluster 
on chromosome 19p13.2. This lncRNA was described 
recently in a publication by Guo et al. [9], who studied a 
cell line generated from portal vein thrombus of an indi-
vidual with hepatocellular carcinoma [10]; the investiga-
tors showed ICR bound to and stabilized the ICAM-1 
transcript, leading to increased ICAM-1 protein expres-
sion. Prior to considering ICR blockade as a treatment 
of retinal vasculopathy, it is essential to understand how 
disease-relevant stimuli trigger transcription of ICR. To 
date, however, the ICR promoter has not been charac-
terized. Thus, we undertook a comprehensive in silico 
analysis of ICR promoter to identify potential TF binding 
sites (TFBSs), as well as associations between TFBSs and 
single nucleotide polymorphisms (SNPs). We also veri-
fied that human retinal endothelial cells expressed ICR.
Main text
Functionally constrained elements in ICR gene promoter 
regions
Conserved sequences across orthologous promoters 
may identify TFBSs of functional relevance; conserved 
sequences signify genomic regions that have resisted 
evolutionary mutation over time, implying a functional 
constraint [11]. Sequences for the human ICR gene and 
an orthologous mouse gene have been manually anno-
tated by the HAVANA (Human and Vertebrate Analysis 
and Annotation) project and lodged with Ensembl [12] 
(human: AC011511.5 and ENSG00000267607.1; mouse: 
AC159314.1 and ENSMUSG00000110790). The human 
gene consists of a single exon that begins in the ICAM4-
ICAM5 intergenic region, spans the entire ICAM4 gene, 
and overlaps the 3′ untranslated region (UTR) of ICAM1 
(Fig.  1). The mouse gene, which is located on chromo-
some 9, also spans Icam4 and overlaps the 3′ UTR of 
Fig. 1 Genomic structure of human ICAM-1-related (ICR) long non-coding RNA. Positions of annotated human ICR gene transcript 
(AC011511.5-201, solid line: ENST00000589379.1) and predicted alternative transcript (based on annotated mouse sequence: AC159314.1-201, 
dashed line: ENSMUST00000216917.1), both located on the anti-sense strand, are indicated in relation to positions of ICAM1 (ENST00000264832.7), 
ICAM4 (ENST00000380770.3) and ICAM5 (ENST00000221980.4) on chromosome 19p13.2 (genome build = GRCh38.p10; grey indicates coding 
sequence). Genome evolutionary rate profiling (GERP) identifies evolutionarily constrained elements within a region 500 base pairs upstream of 
the transcription start sites of the human (A: conserved across 25 eutherians) or mouse (B: conserved across 27 eutherians) ICR gene sequences, 
plus two polyadenylation signals at the 3′ end of both ICR gene sequences (C: conserved across 26 or 24 eutherians). Phenotype-associated 
single nucleotide polymorphisms (SNPs) predicted to impact binding of factors that may regulate ICR gene transcription are showed in boxes that 
correspond to GERP-defined elements
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Icam1, but has 2 exons: the first exon begins within 
intron 1 of Icam5 and continues across exon 1 of Icam5, 
and the second exon begins in the Icam4-Icam5 inter-
genic region and spans Icam4 (Fig. 1). Since locations of 
the transcription start site (TSS) and, by extrapolation, 
the promoter region, differ between human and mouse 
genes, we conducted separate analyses to identify regions 
of constrained DNA sequence across multiple eutherians.
Genomic evolutionary rate profiling (GERP) was per-
formed using the Ensembl genome browser (Ensembl 
release 89—May 2017) [12] to identify evolutionarily con-
strained elements across annotated eutherian sequences 
located within the region 500  base pairs (bp) upstream 
of the human TSS and the mouse TSS [13]. The human 
genome build was GRCh38.p10, and the mouse genome 
build was GRCm38.p5. Genome sources for other 
eutherians are listed in Additional file  1: Table  S1. One 
GERP-constrained element of 115 bp (located at − 276 to 
− 390 bp relative to the TSS) in the human ICR promoter 
was common to 25 genomes; the dolphin sequence was 
excluded, as the match was incomplete across the region. 
A second GERP-constrained element of 68 bp (located at 
− 177 to − 244  bp relative to the TSS) in the promoter 
of the orthologous mouse gene located on chromosome 
9 was conserved across 27 genomes; the pika and lesser 
hedgehog tenrec sequences were similarly excluded due 
to incomplete matching. The proximity of these con-
served, non-coding DNA sequences to the human or 
mouse TSS indicate a likely role in regulating ICR gene 
expression. Interestingly, the GERP-constrained element 
in the mouse gene is conserved in the human genome, 
suggesting a second ICR transcript—with two exons—
may exist in the human. Two polyadenylation signals at 
the 3′ end of the ICR gene are also conserved across 26 
and 24 eutherian genomes, including human and mouse.
Transcription factor binding sites within conserved ICR 
gene promoter regions
The GERP-constrained elements—plus 10  bp upstream 
sequence and 10  bp downstream sequence—within the 
defined promoter regions of the human ICR and orthol-
ogous mouse genes were interrogated for predicted 
TFBSs in the ‘General Core Promoter Elements’ and 
‘Vertebrates’ sections of Matrix Library 10.0 (October 
2016) using MatInspector [14] in Genomatix Software 
Suite (http://www.genom atix.de): the ‘Common TFs’ 
search tool was used; ‘Core similarity’ was set at 0.75; 
and ‘Matrix similarity’ was set at optimized, to mini-
mize false positives for individual matrices. Searching 
the human element identified 5 matrix families (contain-
ing 15 matrices) common to all 24 eutherian sequences, 
plus one additional family (containing 2 matrices) in 23 
of the 24 sequences. These matrices predicted TFBSs 
for gene regulators including: HIF1, NRF1, MYC-MAX, 
BHLHE40, XBP1 and STAF. Searching the mouse ele-
ment identified one matrix family (containing 8 matrices) 
in 24 of 25 eutherian sequences, a second family (contain-
ing 5 matrices) in 23 of 25 sequences, and a third fam-
ily (containing 3 matrices) in 19 of 25 sequences. These 
matrices predicted TFBSs for DNA-binding factors that 
include: RFX1, AP-1 and BACH2. Matrix families, matri-
ces and predicted binding sites are listed in Table 1, and 
sequences and locations corresponding to each matrix 
are provided in Additional file 2: Table S2. The spectrum 
of TFBSs assigned to the ICR gene promoter in our anal-
ysis is consistent with transcription in response to a wide 
range of pathological stimuli that include hypoxia, and 
metabolic and inflammatory proteins.
Single nucleotide polymorphisms in proximity to ICR gene 
promoter regions
We sought to identify phenotype-associated SNPs with 
potential to influence transcription of the human ICR 
gene, searching both the ICR-ICAM5 intergenic region 
and 100 bp downstream of the ICR TSS. We also searched 
intron 1 of the ICAM5 gene, since GERP suggested the 
mouse lncRNA might be represented in the human. 
Single nucleotide polymorphisms within these regions 
(plus 25  bp upstream sequence and 25  bp downstream 
sequence) were extracted from the Single Nucleotide Pol-
ymorphism Database of the US National Center for Bio-
technology Information [15]. The Genomatix Software 
Suite SNPInspector was used to search Matrix Library 
(search settings as described for MatInspector analysis) 
for promoter elements predicted to be impacted by these 
SNPs. Results were checked against chromatin immuno-
precipitation-sequencing data in ENCODE (Encyclope-
dia of DNA Elements) [16] to confirm TF binding at SNP 
locations. This analysis identified 3 SNPs in the defined 
region between ICR and ICAM5 plus 100 bp downstream 
of the ICR TSS (rs2569693, rs281439 and rs281440), and 
2 SNPs in intron 1 of ICAM5 (rs2075741 and rs11575074) 
(Fig.  1; Table  2,  Additional File 3: Table  S3). All these 
SNPs have been associated with human disease and/or 
serum levels of the membrane-cleaved form of ICAM-1, 
which is commonly referred to as soluble (s)ICAM-1.
The rs2569693 SNP has been associated with suscep-
tibility to systemic lupus erythematosus across different 
human populations [17], and with sICAM-1 levels [18]. 
Analysis identifies the location of this SNP to coincide 
with binding sites for numerous TFs, including MYC 
and SCAN domain family members, and predicts the 
minor allele will cause loss of sites for MYC family 
member, MAZR, and SCAN domain family member, 
ZKSCAN3, plus gain of a site for MOK2. The minor 
allele at rs281439 has been associated with increased 
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risk of breast cancer and progression of the cancer [19]. 
Multiple TFs, including USF family members, bind at 
this position, and the minor allele may code loss of the 
USF binding site, plus gain of E2F6, GCM1 and XCPE 
binding sites. The rs281440 minor allele has been 
linked to reduced levels of sICAM-1 [20]; it is predicted 
to cause no gains of binding motifs, but loss of several; 
however, ENCODE identified no TFs that bound this 
position, and thus conclusions on binding activity are 
not possible at this time. The minor allele at rs2075741 
has been associated with breast and prostate cancer 
[19], and elevated levels of sICAM-1 [20]. Several TFs 
are predicted to bind at this site; no TFBS is lost with 
the minor allele, but a new MTE (designated DMTE in 
Genomatix Software Suite) binding sequence may be 
created. Similarly, analysis of rs11575074 minor allele, 
which also has been linked with elevated sICAM-1 
levels [21] reveals no losses in known TFBSs, but sites 
for MYBL1, PTF1 and MEIS1-HOXA9 may be gained. 
Our findings suggest at least 4 of 5 SNPs are likely to 
Table 1 Predicted transcription factor binding sites in  evolutionarily conserved elements, as  identified by  genomic 
evolutionary rate profiling of the sequence located 500 bp upstream of human ICAM-1-related gene transcription start 
sites
a Matrix nomenclature is defined by MatInspector [7]. Matrices predict transcription factor binding sites; matrix families group individual matrices that have similar 
binding properties
Human sequence Matrix  familya Matrixa Description
Annotated V$HIFF V$ARNT.01 AhR nuclear translocator homodimers
V$HIF1.02 Hypoxia inducible factor
V$CLOCK_BMAL1.01 Clock/BMAL1, NPAS2/BMAL1 heterodimers
V$HRE.02 Hypoxia-response elements
V$HRE.03 Hypoxia response elements, HIF1a/ARNT heterodimers
V$HASF V$HAS.01 HIF-1 ancillary sequence
V$NRF1 V$NRF1.01 Nuclear respiratory factor
V$NRF1.02 Nuclear respiratory factor
V$EBOX V$MNT.01 MAX binding protein
V$MYCMAX.02 MYC-MAX binding sites
V$MYCMAX.03 MYC-MAX binding sites
V$NMYC.01 N-myc
V$USF.04 Upstream stimulating factor ½
V$HESF V$DEC1.02 Basic helix-loop-helix protein E40 (BHLHE40)
V$HELT.01 Hey-like transcriptional repressor
V$CREB V$XBP1.01 X-box binding protein 1
V$TAXCREB.02 Tax/CREB complex
V$STAF V$STAF.01 Se-Cys tRNA gene transcription activating factor
Predicted (based on mouse) V$XBBF V$RFX1.02 X-box binding protein RFX1
V$RFX2.02 Regulatory factor X, 2
V$RFX3.01 Regulatory factor X, 3
V$RFX4.01 Regulatory factor X, 4
V$RFX4.03 Regulatory factor X, 4
V$RFX5.02 Regulatory factor X, 5
V$XBOX.01 Motif bound by RFX proteins
V$MIF1.01 Myc Intron-binding protein (MIBP)/RFX complex
V$AP1F V$AP1.01 Activator protein 1
V$AP1.02 Activator protein 1
V$BATF.01 Basic leucine zipper TF
V$FOSL1.01 Fos-like antigen 1
V$JUNB.01 Jun-B
V$AP1R V$BACH2.02 BTB and CNC homology 1, basic leucine zipper TF 2
V$MARE_ARE.01 Antioxidant response elements
V$NFE2.01 NF-E2 p45
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influence TF binding to the ICR gene promoter, and 
thus alter the level of ICR and ICAM-1 expression.
Expression of ICR by human retinal endothelial cells
Given that our interest in ICR relates to its potential as 
a therapeutic target for ICAM-1 in retinal vasculopa-
thy, we wanted to verify the expression and induction 
of ICR in endothelial cells isolated from human retinae. 
Tumor necrosis factor-α has been associated with the 
spectrum of retinal vasculopathies [1], and its signaling 
pathways involve TFs that recognize the TFBSs identi-
fied in our ICR promoter analysis [22, 23]. We generated 
endothelial cell isolates from four paired human retinae, 
using the method that we have previously described in 
detail [1]. Cells were cultured in MCDB-131 medium 
(Sigma-Aldrich, St. Louis, MO), supplemented with 10% 
heat-inactivated fetal bovine serum (FBS) (HyClone-GE 
Healthcare Life Sciences, Logan, UT) and endothelial 
growth factors (EGM-2 SingleQuots supplement, omit-
ting FBS, hydrocortisone and gentamicin; Clonetics-
Lonza, Walkersville, MD) at 37  °C and 5%  CO2 in air, 
and used at passage 1 or 2. Confluent cells were treated 
with fresh medium alone or containing TNF-α (10  ng/
mL, R&D Systems, Minneapolis, MN) for 4 h, and lysed 
with Buffer RLT (Qiagen, Hilden, Germany). Total RNA 
was extracted using the RNeasy mini kit (Qiagen), and 
reverse-transcribed using iScript Reverse Transcrip-
tion Supermix for RT-qPCR (Bio-Rad, Hercules, CA). 
Quantitative real-time polymerase chain reaction was 
performed following standard methodology, using iQ 
SYBRGreen Supermix (Bio-Rad) and on the CFX96 
Connect Real-Time PCR Detection System (Bio-Rad) 
[24]. Relative expression was calculated in the Gene 
Expression Analysis module of CFX Manager v3.1 (Bio-
Rad), which uses the  2−ΔΔCt method [25], normalizing to 
two stable reference genes. Primer sequences are given 
in Additional file 4: Table S4. As presented in Fig. 2, we 
observed that retinal endothelial cell isolates from all 
four human retinae expressed ICR and ICAM-1. Cellu-
lar expression of ICR, as well as ICAM-1 transcript, was 
significantly increased (p < 0.05: Student t test, 2-tailed) 
following exposure to TNF-α. Both level of ICR expres-
sion and degree of induction varied between individual 
donors.
Limitations
  • Our analysis of the ICR gene promoter focused on 
evolutionarily conserved genomic sequences located 
within 500 bp upstream of the TSS. While the major-
ity of TFBSs are expected to lie close to the TSS, it is 
possible that other TFBSs exist outside these regions.
  • This investigation was conducted in silico, and there-
fore it predicts candidate TFBSs, some of which may 
not be confirmed in biological studies. The compu-
tational analysis was comprehensive, but also limited 
by the capacity of present software tools and data-
base annotations.
  • We verified expression and induction of ICR in 
human retinal endothelial cells, since our interest in 
this lncRNA relates to the regulation of ICAM-1 pro-
tein expression in retinal vasculopathy. Our observa-
tions may not apply to all human cell populations.
Table 2 Phenotype-associated single nucleotide polymorphisms (SNPs) and predicted impact of minor allele on binding 
sites for transcription factors within the human ICAM-1-related (ICR) gene promoter
 sICAM-1 soluble intercellular adhesion molecule 1
SNP Alleles Minor allele Transcription factors 
with binding sites in ICR 
promoter
Impact of minor allele on binding sites
Frequency Associations Loss Gain
rs2569693 C/T 0.31 Systemic lupus ery-
thematosus [1]
sICAM-1 level [18]
ELF1, POL2, NFKB, MAX, 
CMYC, E2F6, MXI1, FOXA1, 
CHD2, HMGN3, ZNF263
PLAGL1, WT1, EGR2, 




rs281439 C/G 0.32 Breast cancer [19] USF1, USF2, USF3, FOXA1, 
SIN3AK20, POL2, NFKB, 
MAX, CMYC, E2F6, MXI1, 
POL24H8, TCF12, BHLHEAD, 
HMGN3, IRF1, TBP, YY1, 
ZNF263
USF E2F6, GCM1, XCPE
rs281440 A/G 0.30 sICAM-1 level [20] POL2, TBP, EGR1, SRF, IRF, 
POL24H8, GATA2, ZNF263
KKLF, ZBTB7, LRRFIP1, E2F4
NM23, MAZR
none
rs2075741 G/C 0.33 Breast cancer [19]
Prostate cancer [19]
sICAM-1 level [20]
POL2, TAF1, ZNF263 None DMTE
rs11575074 G/A 0.07 sICAM-1 level [21] POL2, TAF1, SUZ12, ZNF263 NF1B MYBL1, MEIS1A_ HOXA9, PTF1
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Fig. 2 Expression of intercellular adhesion molecule (ICAM)-1-related (ICR) and ICAM-1 by human retinal endothelial cells. Primary endothelial cells 
were individually isolated from retinae of four different human donors, and exposed to tumor necrosis factor (TNF)-α-supplemented or control 
medium for 4 h (n = 3 replicate cultures/condition). a Graph shows mean cycle threshold values obtained in quantitative real-time polymerase 
chain reaction for ICR and ICAM-1 cDNA. Results for each human donor are represented by a unique shape, and represent (TNF)-α-supplemented 
versus control values. b Graphs show relative expression of ICR and ICAM-1 transcript by human donor. Bars represent mean relative expression, 
with error bars showing standard error of the mean. Reference genes were β-actin and glyceraldehyde-3-phosphate dehydrogenase. Data were 
analyzed by two-tailed Student’s t test
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